ORIC Pharmaceuticals, Inc. (FRA:4TZ)

Market Cap	841.04M +12.8%
Revenue (ttm)	n/a
Net Income	-115.29M
EPS	-1.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	9.85
Previous Close	10.00
Day's Range	9.20 - 9.85
52-Week Range	3.70 - 13.30
Beta	n/a
RSI	47.57
Earnings Date	Feb 18, 2026

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 106
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4TZ

Financial Performance

Financial numbers in USD